1. "Michael Morris"
Formats
  1. Meeting Abstract (243)
  2. Journal Article (241)
  3. Review (16)
  4. Editorial (6)
  5. Book Section (5)
  6. Correspondence (3)
  7. Guidelines (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (518)
  2. Genitourinary Oncology Service (518)
  3. Solid Tumor Oncology Division (518)
  4. Radiology, Department of (155)
  5. GSK Faculty (150)
  6. Molecular Imaging and Therapy Service (132)

More Groups

People
  1. Michael Morris (518)
  2. Howard Scher (211)
  3. Steven Larson (91)
  4. Susan Slovin (88)
  5. Dana Rathkopf (76)
  6. Daniel Danila (51)

More People

Years
  1. 2024 (10)
  2. 2023 (39)
  3. 2022 (50)
  4. 2021 (42)
  5. 2020 (35)
  6. 2019 (39)

More Years

Publications
  1. Journal of Clinical Oncology (216)
  2. Journal of Nuclear Medicine (39)
  3. Clinical Cancer Research (29)
  4. Annals of Oncology (25)
  5. Cancer (16)
  6. European Urology (16)

More Publications

Publishers
  1. American Society of Clinical Oncology (224)
  2. American Association for Cancer Research (39)
  3. Society of Nuclear Medicine (39)
  4. Oxford University Press (34)
  5. Elsevier Science, Inc. (33)
  6. Elsevier Inc. (25)

More Publishers

Results (518)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
    Meeting Abstract

    Sartor, O.; Castellano Gauna, D. E.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N. N.; Crosby, M.; Piulats Rodriguez, J. M.; Flechon, A.; Wei, X. X.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
    Meeting Abstract

    Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Assessing PSA
    Meeting Abstract

    Halabi, S.; Roy, A.; Guo, S.; Rydzewska, L.; Godolphin, P. J.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Carducci, M. A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Armstrong, A. J.; Chi, K. N. N.; de Bono, J. S.; Herrmann, K.; Krause, B.; Rahbar, K.; Sartor, O.; Tagawa, S. T.; Nagarajah, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Association of baseline quantitative [68Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [177Lu]Lu-PSMA-617: a VISION sub-study
    Meeting Abstract

    Kuo, P. H.; Morris, M.; Kendi, A. T.; Rahbar, K.; Wei, X. X.; Fang, B.; Armstrong, A. J.; Hesterman, J.; Chi, K.; de Bono, J.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
    Clinical Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • A pilot study of stereotactic body radiotherapy and (177)Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer
    Meeting Abstract

    Imber, B. S.; Bodei, L.; Humm, J.; Ionescu, A.; Wu, W.; Grkovski, M.; O'Donoghue, J.; Reddy, R. P.; Rimner, A.; Shasha, D.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • SNMMI consensus statement on patient selection and appropriate use of (177)Lu-PSMA-617 radionuclide therapy
    Guidelines

    Hope, T. A.; Antonarakis, E. S.; Bodei, L.; Calais, J.; Iravani, A.; Jacene, H.; Koo, P. J.; Morgans, A. K.; Osborne, J. R.; Tagawa, S. T.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save